XML 42 R32.htm IDEA: XBRL DOCUMENT
v3.24.0.1

REVENUE (Tables) | 3 Months Ended
--- | ---
Jan. 31, 2024
Revenue from Contract with Customer [Abstract] |
Disaggregation of Revenue | The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:
| Three Months Ended January 31,
| 2024 |  | 2023
| Life Sciences and Applied Markets |  | Agilent CrossLab |  | Diagnostics and Genomics |  | Total |  | Life Sciences and Applied Markets |  | Agilent CrossLab |  | Diagnostics and Genomics |  | Total
| (in millions)
Revenue by Region |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Americas | $ | 244 |  |  | $ | 164 |  |  | $ | 222 |  |  | $ | 630 |  |  | $ | 286 |  |  | $ | 154 |  |  | $ | 247 |  |  | $ | 687 |
Europe | 224 |  |  | 111 |  |  | 123 |  |  | 458 |  |  | 239 |  |  | 98 |  |  | 119 |  |  | 456 |
Asia Pacific | 378 |  |  | 130 |  |  | 62 |  |  | 570 |  |  | 418 |  |  | 129 |  |  | 66 |  |  | 613 |
Total | $ | 846 |  |  | $ | 405 |  |  | $ | 407 |  |  | $ | 1,658 |  |  | $ | 943 |  |  | $ | 381 |  |  | $ | 432 |  |  | $ | 1,756 |
The following table presents the company’s total revenue disaggregated by end markets and by revenue type:
|  |  | Three Months Ended
|  |  | January 31,
|  |  |  |  | 2024 |  | 2023
|  |  |  | (in millions)
Revenue by End Markets |  |  |  |  |  |  |
Pharmaceutical and Biopharmaceutical |  |  |  |  | $ | 565 |  |  | $ | 639 |
Chemicals and Advanced Materials |  |  |  |  | 392 |  |  | 406 |
Diagnostics and Clinical |  |  |  |  | 228 |  |  | 239 |
Food |  |  |  |  | 157 |  |  | 160 |
Academia and Government |  |  |  |  | 150 |  |  | 146 |
Environmental and Forensics |  |  |  |  | 166 |  |  | 166 |
Total |  |  |  |  | $ | 1,658 |  |  | $ | 1,756 |
Revenue by Type |  |  |  |  |  |  |
Instrumentation |  |  |  |  | $ | 630 |  |  | $ | 759 |
Non-instrumentation and other |  |  |  |  | 1,028 |  |  | 997 |
Total |  |  |  |  | $ | 1,658 |  |  | $ | 1,756 |
Contract Liabilities and Changes in Balances | The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the three months ended January 31, 2024:
|  | Contract Liabilities
|  | (in millions)
Ending balance as of October 31, 2023 |  | $ | 616 |
Net revenue deferred in the period |  | 254 |
Revenue recognized that was included in the contract liability balance at the beginning of the period |  | (229) |
Change in deferrals from customer cash advances, net of revenue recognized |  | (5) |
Currency translation and other adjustments |  | 8 |
Ending balance as of January 31, 2024 |  | $ | 644 |

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration